Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2017-02-22 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于召开2017年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2017 second extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes information on shareholder voting, meeting registration, and proxy authorization. There is no financial data, earnings, or report content. The document is an announcement related to a shareholder meeting rather than the meeting materials or results themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2017-02-22 Chinese
第八届董事会第六十八次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of a board meeting resolution regarding a major asset restructuring and continued trading suspension. It includes specifics about the transaction, involved parties, voting results, and procedural details. It is not a full financial report but an official announcement of board decisions and corporate actions related to a major asset restructuring. The document length is under 5,000 characters and it does not contain financial statements or detailed financial analysis. It is not a report publication announcement since it contains substantive content about the board meeting and resolutions. The content fits best under Capital/Financing Update (CAP) as it relates to a major asset restructuring and financing activities.
2017-02-22 Chinese
关于为关联方提供担保暨关联交易的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company 中源协和细胞基因工程股份有限公司 regarding the progress of providing guarantees to related parties and related party transactions. It details the guarantee agreements, amounts, and terms, as well as approvals from various shareholder meetings. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory announcement about guarantees and related party transactions, which fits best under the category of Regulatory Filings (RNS) as it does not match any other more specific category such as capital updates or management changes.
2017-02-21 Chinese
重大资产重组继续停牌公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the continuation of a trading suspension due to a major asset restructuring. It details the board meeting decisions, the background and reasons for the restructuring, the transaction framework, and the expected timeline for resumption of trading. The document does not contain financial statements or detailed financial analysis but is focused on the announcement of the ongoing status of a major asset reorganization and the related stock suspension. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. It is an official announcement related to a major asset restructuring event and the continuation of stock suspension. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset restructurings and related stock suspension announcements. The document length is under 5,000 characters, but it is substantive and not merely a notice of report publication or certification, so it is not RPA or RNS. Confidence is high given the clear focus on major asset restructuring and stock suspension continuation.
2017-02-10 Chinese
关于签署重大资产重组框架协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding the signing of a framework agreement for a major asset restructuring. It details the parties involved, the nature of the transaction (purchase of 100% equity of Shanghai Aoyuan Investment Management Co., Ltd.), the preliminary terms, and the need for further approvals including from regulatory bodies such as the China Securities Regulatory Commission. The document is an announcement of a transaction proposal and framework agreement, not a full report or financial statement. It does not contain comprehensive financial data or results but rather outlines the intent and conditions for a major asset restructuring. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset acquisitions or restructurings.
2017-02-10 Chinese
独立董事关于重大资产重组继续停牌的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from independent directors regarding the continuation of a trading suspension due to a major asset restructuring. It references regulatory guidelines and the board meeting approving the suspension extension. The content focuses on the procedural and governance aspects of the asset restructuring and the trading halt, not on the actual financial results or detailed transaction disclosures. It is not a full report, earnings release, or financial statement. It is also not a simple announcement of a report publication. The document is best classified as a Regulatory Filing (RNS) because it provides regulatory compliance information and governance-related disclosure about the asset restructuring process and trading suspension, without constituting a full report or financial filing itself.
2017-02-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.